Brendan Smith, an analyst from TD Cowen, maintained the Buy rating on Twist Bioscience (TWST – Research Report). The associated price target remains the same with $58.00.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Brendan Smith has given his Buy rating due to a combination of factors that position Twist Bioscience for success in the industry. Despite recent tariff concerns affecting the broader tools sector, Twist’s minimal revenue exposure to China and its manufacturing operations being entirely based in the United States provide a competitive advantage. This situation allows Twist to avoid the tariffs that impact many of its competitors, thereby enhancing its market position and potential for profit margin improvement.
Furthermore, Smith notes the company’s strong fiscal year 2025 outlook, with expectations of continued success in strategic goals and market share acquisition. The raised guidance for FY25 is seen as reasonable and achievable, reinforcing confidence in Twist’s growth durability and operational leverage. Additionally, the company’s financial stability, with sufficient cash on hand, supports its path to profitability, and Smith’s recent interactions with Twist’s management have strengthened his conviction in their strategic direction. These factors collectively justify the Buy rating for Twist Bioscience, with a price target set at $58.
Smith covers the Healthcare sector, focusing on stocks such as Twist Bioscience, BioLife Solutions, and Ginkgo Bioworks Holdings. According to TipRanks, Smith has an average return of 8.2% and a 65.52% success rate on recommended stocks.
In another report released today, Barclays also maintained a Buy rating on the stock with a $52.00 price target.